Investors purchased shares of Mylan NV (NASDAQ:MYL) on weakness during trading on Tuesday. $29.92 million flowed into the stock on the tick-up and $16.21 million flowed out of the stock on the tick-down, for a money net flow of $13.71 million into the stock. Of all stocks tracked, Mylan had the 29th highest net in-flow for the day. Mylan traded down ($0.12) for the day and closed at $26.60
A number of analysts have recently commented on MYL shares. Zacks Investment Research raised shares of Mylan from a “hold” rating to a “buy” rating and set a $33.00 target price for the company in a research note on Tuesday, January 8th. UBS Group cut shares of Mylan from a “buy” rating to a “neutral” rating and cut their target price for the stock from $54.00 to $32.00 in a research note on Wednesday, January 23rd. Mizuho reissued a “neutral” rating on shares of Mylan in a research note on Thursday, January 31st. Sanford C. Bernstein cut shares of Mylan from an “outperform” rating to a “market perform” rating and set a $33.00 target price for the company. in a research note on Wednesday, February 27th. Finally, BMO Capital Markets boosted their target price on shares of Mylan to $40.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 27th. They noted that the move was a valuation call. Three equities research analysts have rated the stock with a sell rating, five have issued a hold rating and fifteen have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $39.89.
The company has a market cap of $13.80 billion, a PE ratio of 5.81, a PEG ratio of 1.13 and a beta of 1.48. The company has a current ratio of 1.39, a quick ratio of 0.83 and a debt-to-equity ratio of 1.17.
In related news, insider Paul Campbell sold 11,533 shares of the company’s stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $27.50, for a total transaction of $317,157.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 0.81% of the stock is currently owned by corporate insiders.
A number of hedge funds and other institutional investors have recently made changes to their positions in MYL. Bank of New York Mellon Corp boosted its holdings in Mylan by 8.7% in the 3rd quarter. Bank of New York Mellon Corp now owns 10,226,277 shares of the company’s stock valued at $374,280,000 after purchasing an additional 818,059 shares during the last quarter. Standard Life Aberdeen plc boosted its holdings in Mylan by 6.7% in the 3rd quarter. Standard Life Aberdeen plc now owns 268,287 shares of the company’s stock valued at $9,820,000 after purchasing an additional 16,877 shares during the last quarter. LPL Financial LLC boosted its holdings in Mylan by 33.4% in the 3rd quarter. LPL Financial LLC now owns 74,401 shares of the company’s stock valued at $2,723,000 after purchasing an additional 18,612 shares during the last quarter. Man Group plc acquired a new position in Mylan in the 3rd quarter valued at about $4,743,000. Finally, Putnam Investments LLC boosted its holdings in Mylan by 92.4% in the 3rd quarter. Putnam Investments LLC now owns 14,118 shares of the company’s stock valued at $517,000 after purchasing an additional 6,779 shares during the last quarter. 83.68% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY WARNING: “Investors Buy Shares of Mylan (MYL) on Weakness” was posted by Dakota Financial News and is the sole property of of Dakota Financial News. If you are accessing this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be accessed at https://dakotafinancialnews.com/2019/04/24/investors-buy-shares-of-mylan-myl-on-weakness.html.
Mylan Company Profile (NASDAQ:MYL)
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS.
Recommended Story: How to interpret the current ratio
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.